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MEDICATION ADHERENCE IN DIABETIC MELLITUS: A REVIEW OF 
BARRIERS AND INTERVENTIONS 
 
SENMIAO ZHAN 
 
 
ABSTRACT 
 Poor adherence is common in patients with diabetes mellitus and other 
chronic diseases that require extensive self-management.  This behavior has 
been linked to increased complications, mortality rate, and health care costs. 
Although much effort has been put into studying the barriers to adherence and 
ways to improve both patient self-care and clinical outcomes, little success can 
be observed in the long run.  Literature review of studies related to medication 
adherence in diabetes has shown a lack of uniformity in study parameters and 
statistical analysis making the juxtaposition of studies difficult and unreliable.  
Intervention studies in the field have shown general improvement in adherence 
rate in a short period of time, but rarely making any significant differences in 
clinical outcomes.  Since diabetes mellitus is a chronic disease, it would be 
important to design studies measuring long term effects of interventions in the 
future.    
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INTRODUCTION 
Diabetes Mellitus (DM), or diabetes, is a serious and complex metabolic 
disease that disturbs the lives of millions globally (Guariguata et al., 2013). 
According to the Centers for Disease Control (CDC), about 25.8 million people in 
the United States alone were affected by diabetes in the year of 2010, and about 
35% of adults above the age of 20 are prediabetic based on their hemoglobin 
A1c (HbA1c) levels (CDC, 2011).  Although much new information has been 
gained through various scientific studies regarding the cause of diabetes 
(Schulze & Hu, 2014), there is a fast growing trend in the prevalence of the 
disease (Danaei et al., 2011; Guariguata et al., 2013).  With more people being 
diagnosed and treated for diabetes, there is also an increase in the economic 
burden.  In 2012, it has been estimated that the expenditure related to diabetes 
was about $245 billion ($176 billion in direct medical cost and $69 billion in lost 
productivity) in the US (Association, 2013).   Due to the substantial costs and 
detrimental effects of the disease, prevention and reduction of diabetes is of 
great importance. 
Generally speaking, DM is a disease where the insufficiency of insulin 
and/or tissues’ lack of response to insulin leads to abnormal levels of glucose in 
the blood.  Although the diagnosis of DM is made primarily through the 
concentration of plasma glucose (fasting plasma glucose > 126mg/dL for two 
days) (Koeppen & Stanton, 2009), the pathological manifestation of the disease 
can be observed through various systems in the body (Figure 1).   
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Figure 1. Major complications from diabetes: The figure depicts some of 
the microvascular and macrovascular complications from diabetes 
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Complications of prolonged hyperglycemia, or high blood sugar, are 
categorized into microvascular and macrovascular.  Microvascular complications 
include retinopathy, neuropathy, and nephropathy.  Retinopathies are retinal 
abnormalities and are the leading cause of new onset blindness in the US (Fong 
et al., 2004). It has been shown through various studies that highly regulated 
glycemic control has protective effects against the development of retinopathy 
(Fong et al., 2004).  Peripheral nerve dysfunction (neuropathy) can lead to 
problems such as sensory loss and paresthesia in patients with DM, particularly 
in the lower extremities.  In severe cases, foot ulceration and injuries can even 
result in amputation.   To disturb the body’s homeostasis even more, 
hyperglycemia can damage the renal functioning in patients.  Nephropathy as a 
result of DM is the leading cause of renal failure in the US (Fowler, 2008).  
Similar to retinopathy, it has been shown that glycemic control is strongly 
associated with decreased incidence of both neuropathy and nephropathy as 
well (Fowler, 2008; Gross et al., 2005).   
The macrovascular complications of DM manifest themselves as an 
accelerated rate of developing atherosclerosis.  The thickening of the arterial wall 
is likely the result of vascular injuries and chronic inflammation.  Due to the 
macrovascular complications, diabetic patients are more likely to develop 
cardiovascular diseases (CVD), such as coronary artery disease, and have 
increased chances of myocardial infarction and stroke (Brownlee, 2001; Fowler, 
2008; Koeppen & Stanton, 2009).  This chance of developing CVD is augmented 
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when the patient also has hypertension and/or dyslipidemia (Haffner, 1999; 
Sowers, Epstein, & Frohlich, 2001).   
The majority of diabetic patients can be classified into two groups.  Type 1 
DM (T1DM), or insulin-dependent DM, accounts for a small portion of the diabetic 
patient population.  It is hallmarked by the destruction of beta cells in the 
pancreas, often occurring through autoimmune mechanisms.  Since beta cells 
are the producers of insulin, T1DM patients have impaired insulin production; 
therefore, exogenous insulin is an effective treatment to help prevent ketosis.  
The vast majority of the T1DM patients are diagnosed in childhood, but the onset 
can happen any time.  Type 2 DM (T2DM), on the other hand, makes up about 
90% of the diagnosed diabetic population.  T2DM differs from T1DM in that 
individuals are still able to produce insulin, either normally or at a diminished rate; 
however, key organs are unable to sense the presence of insulin.  Although the 
mechanism varies from case to case, the underlying problem with T2DM seems 
to be insulin resistance (Koeppen & Stanton, 2009).   
Due to the complex nature of the disease, treatment for T2DM can be very 
complex.  In order to gain glycemic control, patients may need to take certain oral 
treatments and/or insulin along with adhering to careful diet plans and exercise 
regimes.   Additionally, patients also have to monitor their blood glucose 
regularly.  With the progression of the disease, patients have to take additional 
medications to manage the microvascular and macrovascular complications.  In 
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other words, glycemic control is strictly dependent on the patients’ abilities to 
self-manage.    
 
Medication adherence 
In order to measure how well patients follow their medication regime, 
concepts such as persistence, adherence, and compliance have been used in 
literature (Cramer, 2004; Kravitz & Melnikow, 2004; Osterberg & Blaschke, 
2005).  It should be noted that the definition of these terms are not uniformly 
accepted.  Some consider compliance and persistence to be synonymous with 
adherence, where the terms are defined as “the extent to which a patient is 
consistent in following medical or health advice (Dunbar-Jacob & Mortimer-
Stephens, 2001; Haynes, Ackloo, Sahota, McDonald, & Yao, 2008).”  Others 
consider persistence as the duration for which a patient is adherent or compliant 
to certain medications (J. K. Lee, Grace, & Taylor, 2006).  Some literature even 
suggests that “adherence” is a better term because “compliance” is making the 
assumption that the patient is passively following doctor’s orders (Osterberg & 
Blaschke, 2005).  Either way, the assessment of medication utilization behavior 
can be critical to the outcome of the treatment due to the obvious reason that, if a 
patient is not taking the medication as prescribed, the intended therapeutic 
effects cannot occur.  For the purpose of this paper, adherence and compliance 
will be used interchangeably. 
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Clinical studies of medication adherence have shown varied results.  In a 
2004 quantitative review of adherence studies from the past five decades, it was 
found that, within the 569 studies assessed, the rate of adherence ranged from 
~5% to 100%, with an overall average of ~75% (DiMatteo, 2004).  One of the 
factors that could contribute to such large variability is the lack of a numerical 
consensus on what is considered to be adequate adherence.  Although 
adherence is a continuous factor that could be expressed in a percentage scale 
(100% adherence meaning taking all medications on time), most studies consider 
adherence and non-adherence as dichotomous variables, where a cutoff is 
established.  In an effort to unify measures of adherence in recent publications, 
the conventional “good adherence” has been established at greater than 80% 
(Dunbar-Jacob & Mortimer-Stephens, 2001); however, it is not uncommon to see 
studies using cutoffs higher or lower than 80% (Osterberg & Blaschke, 2005). 
Another factor that could contribute to the large disparities in medication 
adherence is the type of disease the medications are treating.  In the 
aforementioned review study, compliance rate was the highest in HIV and lowest 
in sleep disorders (DiMatteo, 2004).   
Study design can also play a key role in data variation.  There are different 
methods that studies can utilize to gather patient adherence information, each 
with its own set of strengths and weaknesses.  The methods can be generally 
divided into three groups: direct, indirect-voluntary, and indirect-involuntary.  
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Table 1 provides a summary of each method and its advantages and 
disadvantages.   
The direct method consists of biochemical measurements, where samples 
of body fluids provided by patients are assessed for medications (or the 
metabolites), or by directly observing patients taking their medications.  These 
methods can be fairly impractical because they require constant or frequent 
monitoring of the patients.  Depending on how frequently the researchers 
communicate with the patients, the extra attention could result in overestimation 
of patients’ own ability to stay compliant to the medication.  Although these types 
of studies provide a very detailed and objective data set, it is generally costly and 
cannot always be used due to the fact that not all medications have easily 
measurable metabolites.  The amount of effort required to gather data plus the 
costliness of the study makes this method an inadequate way to assess 
adherence in a large population (Vermeire, Hearnshaw, Van Royen, & 
Denekens, 2001).   
The indirect-voluntary measurements for adherence are methods 
dependent on patients’ abilities to report information.  These methods could 
present themselves in the form of surveys with detailed questions regarding 
patients’ medication taking behavior or as records kept by the patients in the form 
of diaries.  Questioning patients regarding their behaviors in the form of 
questionnaires can be an inexpensive and simple way to gather data regarding 
adherence; however, the study would be susceptible to response bias, where the 
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patients might answer questions based on how they expect the healthcare 
providers to want them to answer.  When designing studies that gather patient 
responses, researchers also need to pay close attention to how each question is 
worded because differences in the interpretation of questions can also result in 
response biases.  Since a healthcare provider’s intention is for the patients to 
take their medication and follow the treatment regimes, there could be a gross 
overestimation in the adherence rate reported by patients (Vermeire et al., 2001).   
The indirect-involuntary group of methods consists of pill counts, 
electronic monitoring, and the use of medication refill data.  Pill counts are 
usually conducted through the pharmacy where pharmacists will count the 
remaining number of pills left in a patient’s bottle.  When pill counts are 
conducted through the patient, it becomes a type of patient self-report, and is 
prone to all the biases discussed above in the voluntary section.  However, even 
when pill count is conducted through the pharmacy, patients still can easily alter 
the outcome by discarding the pills or by switching them with other bottles in 
order to appear to be following the treatment regimen.  Although pill counting is 
an attractive method due to its simplicity, it is by no means a good measure of 
adherence due to its lack of reliability (Rudd et al., 1988).   
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Table 1.  Methods used in studying medication adherence: This table compares the pros and cons of various methods 
used to measure adherence. 
 
Method Pros Cons 
Direct  Biochemical measures 
(levels of drug or its 
metabolites in body fluids) 
Highly accurate for drugs that 
does not metabolize easily.  
 
Expensive 
The special attention given to the 
patient might overestimate 
adherence 
Does not work for every medication 
due to variation in metabolism of 
each patient. 
 Directly observe patient 
taking the medication 
Highly accurate  Patients could hide pills 
Overestimation of adherence due to 
special attention 
Indirect 
voluntary 
Patient self-report and 
surveys 
Easily conducted with low cost.   Patients could easily alter their 
answers and distort the data   
 Patient record/diaries Good longitudinal record Patients could easily alter their 
answers and distort the data 
Indirect 
involuntary 
Pill count Simple and inexpensive.  Easily 
quantifiable data 
Patients could easily alter the pill 
numbers  
 Electronic monitors  Simple and easily quantifiable 
data 
Monitoring devices are very 
expensive.  Patients could out-smart 
the system and alter data 
 Pharmacy refill data Data is already entered through 
pharmacy.  Easily obtainable 
Prescription refill does not equal 
actual ingestion of medication 
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 As technological advancements are made, electronic monitoring systems 
are becoming more available for adherence studies.  Electronic devices can 
record time stamped data each time the patient opens a bottle or canister.  The 
newer devices can even transmit such data via internet, making the data 
gathering process highly accurate and simplified (J. Hughes, Sterns, 
Mastandrea, & Smith, 2013).  Through the use of electronic monitoring systems, 
phenomena such as “white-coat adherence” and “drug holidays” have been 
discovered (Osterberg & Blaschke, 2005; Urquhart, 1997).   “Drug holidays” 
refers to lapses in medication adherence longer than three days.  This happens 
to about one sixth of the patient population monthly (Urquhart, 1994).  “White-
coat adherence” on the other hand, refers to the phenomenon where patients are 
more likely to improve their medication-taking behavior five days prior to and post 
an appointment with their provider, and the improvement deteriorates until the 
next appointment (FEINSTEIN, 1990).  Although this approach to studying 
adherence can provide highly precise information on the patients’ medication-
taking behavior, it cannot provide information on whether patients actually ingest 
the medication or how much is ingested.  The patient can also cheat the system 
by taking out the medication without actually ingesting it, or take the wrong 
dosage and thus invalidate the data.  The high cost of the electronic monitoring 
devices also makes it unfavorable to study large sample sizes.   
 There is an increasing trend in adherence studies to utilize pharmaceutical 
refill databases.  Although there are many flaws, the refill data for medication has 
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proven to be a good alternative to direct measurements of compliance (Steiner & 
Prochazka, 1997).  The use of databases is subject to the same type of problems 
as the electronic devices and pill counts, where patient might refill medications 
without actually ingesting them.  Additionally, medication is usually filled on a 
monthly basis, making it difficult to assess the patients’ medication-taking 
behavior within the month.  Regardless, due to the efficiency of current pharmacy 
record systems, near complete records are available for a large group of 
patients.  This means that using the database would give researchers a relatively 
cost-effective way to study the behavior of a great sum of patients.   
Other factors such as selection bias, small sample size, and 
experimenter’s bias can also be attributed to the variations in adherence data.  
There is no one perfect strategy to study adherence.  Even though the flaws of 
experimental designs are known, it is difficult to eliminate the biases due to 
limited resources and the nature of the study population. 
The rate of medication adherence in T2DM patients is quite low, ranging 
from 67-85% for oral hypoglycemic agents (OHAs) to 62-64% for insulin (Cramer, 
2004).  Poor adherence not only reduces the overall efficacy of medications, but 
is also associated with increased complications and higher mortality rates (Ho et 
al., 2006).  Moreover, with the growing number of patients suffering from 
complications and a great number of resources being wasted each year from 
medication omission, non-adherence is becoming a substantial economic 
burden.  All in all, the cost of poor compliance in the United States has been 
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estimated to be around $100 billion each year (D. A. Hughes, Bagust, Haycox, & 
Walley, 2001).   
Improving medication adherence should be one of the main focuses of 
health care providers.  It has been shown that patients who maintain a high rate 
of medication compliance have significantly reduced rates of hospitalization, thus 
costing less in healthcare (Sokol, McGuigan, Verbrugge, & Epstein, 2005).  
There are also other losses such as reduced worker efficiency, death, and 
treatment for other complications that can perhaps be reduced if a better 
adherence rate can be achieved.   
 
Identify poor adherence 
The first step towards improving medication compliance is to recognize 
poor adherence, especially in T2DM patients where signs of non-adherence 
might not be immediately apparent.  In the clinical setting, HbA1c is often used as 
a tool to measure a patient’s long-term glycemic control.  HbA1c is hemoglobin 
that has been glycated by exposure to plasma glucose.  Since the life-span of 
hemoglobin is usually 120 days, once the hemoglobin goes through glycation, it 
will stay glycated for the remainder of its life time.  This feature makes HbA1c a 
great marker because elevated levels of glycated hemoglobin would indicate 
prolonged hyperglycemia.  Patients who are compliant to medication had 
generally lower HbA1c than those who are not.  One study was able to utilize a 
set of questionnaires called the Morisky score in conjunction with HbA1c to 
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identify poorly adherent patients (Krapek et al., 2004).  There are other factors 
associated with patients at a higher risk for medication non-adherence such as 
age, race, and socio-economic status that will be expanded upon later. 
 
Improvement of poor medication adherence 
Once the identification of non-adherence is achieved, there needs to be 
interventions to improve medication compliance.  The types of interventions for 
medication adherence can generally be categorized into five groups: cost based, 
convenience based, reward based, communication based, and finally a 
combination of intervention groups.  Table 2 shows an overview of the groups of 
interventions and some examples of how the interventions could be utilized.  
Although not all of these interventions have been studied with diabetic patients, 
there are similar studies on other chronic diseases such as hypertension and 
cardiovascular diseases that diabetes is closely related to.  The specific data and 
effectiveness of the interventions will be discussed later on.   
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Table 2.  General overview of interventions to improve adherence: Five types of 
interventions with summaries and examples of each. 
Type of 
intervention 
Summary Example 
Cost based Cost based intervention usually 
is achieved through changing 
the cost of medication directly 
or indirectly leading to either 
increased or decreased drug 
acquisition cost.   
 
 Decrease copayments  
 Increase insurance 
coverage  
 
Convenience 
based 
These interventions usually 
involve the increase in 
convenience for the patients to 
either acquire the medication or 
to use the medication. 
 Mail-order pharmacy 
 Getting easier access to 
the pharmacy/medication 
 Simplified dosage regimen  
 Simplified packaging  
 Alternative route of 
medication administration  
 
 
Reward based Patients in this type of 
intervention group either 
receive rewards as a mean of 
achieving certain clinical goals, 
receive rewards in order to help 
them improve their adherence, 
or the reward is given at a 
random chance. 
 
 Financial incentives as a 
reward for achieving certain 
goals. 
 Glucometer or blood 
pressure cuffs awarded to 
the patients as a mean to 
increase self-checkups.   
 A lottery system  
 
 
Communication 
based 
Increased communication 
between healthcare 
provider/patient, patient 
family/patient, patient/patient in 
order to educate or remind 
patients regarding their 
conditions 
 
 Care programs 
 Counseling through various 
means 
 Educational materials 
 Increased home visits or 
phone calls 
 Small group sessions 
 
 
Combination Two or more of the above 
interventions used together 
 Using care programs in 
conjunction with decreased 
copayments 
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The cost-based interventions stem from the idea that cost is one of the 
main players in causing medication non-adherence.  Even if the cost of 
medication is covered by insurance, the bills can stack up from the copayments.  
In fact, many studies have shown that lack of drug coverage is strongly 
associated with decreased use of prescription drugs (Soumerai et al., 2006).  
Additionally, this cost-related non-adherence is most prominent in elderly and in 
disabled patient populations (Soumerai et al., 2006).  There are many sources of 
cost regulations that can be considered when designing cost-based interventions 
to increase medication adherence.  Since penalizing unhealthy behavior by 
increasing cost is unethical and has definitive adverse effect on medication 
adherence (Doshi, Zhu, Lee, Kimmel, & Volpp, 2009), it should be avoided at all 
cost.  Figure 2 displays the general breakdown of medical costs based on patient 
and health insurance.   Several sources of cost contributing to the out-of-pocket 
cost from patients can be observed.  From an intervention stand point, the 
easiest way to reduce expenses is to perhaps reduce copayment, since it is 
usually a flat rate.  Other approaches would be to reduce the patient portion of 
coinsurance, decrease the deductible limit, increase coverage for medication, or 
reduce premiums.   
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Total Cost 
Copayment 
Coinsurance 
Insurance Patient 
Deductible 
Travel and 
other 
expenses 
Premiums 
Exclusions 
Figure 2.  Medical cost breakdown: This figure shows the general cost 
breakdown of medical expenses for a patient that has health insurance. 
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 Convenience based interventions focus on alleviating any inconveniences 
in the process of acquiring or administering the medication for the patients.   One 
example of such an intervention is to give patients easier access to their 
medication by using mail-order pharmacies instead of traveling to their local 
pharmacies since the medication possession rate is higher in patients who use 
mail-order pharmacies (Duru et al., 2010).    
From adherence studies from the past decades, researchers have found 
that frequency of dosing and complexity of treatment regimen is highly correlated 
with reduced adherence (Dezii, Kawabata, & Tran, 2002; Donnan, MacDonald, & 
Morris, 2002; Girvin, McDermott, & Johnston, 1999; Ingersoll & Cohen, 2008).  
Dosage simplification and specialized packaging are both examples of 
interventions based on adding convenience to taking medication.   
 Reward based interventions have been used in many studies to reinforce 
certain behaviors such as smoking cessation, weight loss, and medication 
adherence (Burns, 2007; Volpp, John, et al., 2008; Volpp et al., 2009).  The way 
in which rewards are given can vary between studies.  Although the type of 
rewards are usually financial incentives such as cash payments and shopping 
vouchers, there are also examples of shortening jail sentences as a reward to 
improve psychiatric treatment adherence (Monahan et al., 2005).  In another 
study based on medication use (Volpp, Loewenstein, et al., 2008), the 
researchers used a lottery system in conjunction with electronic monitoring 
devices.   
  18 
 Communication based interventions have been used widely through 
medication adherence studies because it can take various forms.  This category 
of intervention methods can be further divided based on the benefits they 
provide.  Instructional interventions provide patients with more knowledge 
regarding their disease, potential complications, and self-management plans. In 
addition to oral communication, these can take the form of written materials and 
learning programs. Another method of communication based intervention works 
through reinforcement of compliance to medication schedules.  These can 
include automated telephone calls, electronic monitoring systems, or casual 
reminders from health care providers, either through phone calls, home visits, or 
office visits.  A third method of communicative intervention works through 
structured counseling programs.  These programs could take the form of group 
or individual sessions, where patients can discuss social, economic, and 
emotional factors that might otherwise deter them from adherence.   
 Combined interventions usually mix a communication based intervention 
with some other intervention category.  An example of a combined intervention 
would be providing financial incentives to patients while giving them educational 
pamphlets detailing the disease’s complications and self-management plans.   
 The ultimate goal of adherence interventions is not only to alter the 
patients’ behaviors, but also to improve health conditions.  For diabetic patients, 
this means reduced HbA1c levels, rates of microvascular and macrovascular 
complications, inpatient and outpatient hospital visits, and mortality rates.  This 
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means that interventions must have a persisting effect, lasting long after the 
intervention period ends.  One of the goals this paper is to compare various 
intervention methods and assess their relative effectiveness in both increasing 
medication adherence and improving clinical outcomes.  
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PUBLISHED STUDIES 
Literature searches were conducted through Google Scholar, PubMed, 
and Web of Knowledge, inputting keywords that generally relate to medication 
adherence in diabetes (eg. adherence, compliance, non-adherence, intervention, 
diabetes, and diabetes mellitus).  Instead of conducting an exhaustive review that 
encompasses all of the literature published about the topic in the past two 
decades, a limited number of reviews and studies were selected due to study 
design and relevancy to this paper.  Relevant review articles were further 
reviewed and screened for citation of studies that fit the search criteria.   
 Initially, articles were separated into two groups: medication adherence 
studies for diabetes, and adherence studies for non-diabetic diseases.  The 
diabetic articles were further divided into “measures of behavior and/or HbA1c 
only”, “intervention with measures of behavioral outcomes”, and “intervention with 
measure of both behavioral and clinical outcomes”.  The “measures of behavior 
and/or HbA1c only” articles will be used to distinguish factors that help identify 
non-adherence, while the intervention articles will be assessed for effectiveness 
of the said interventions.  Each article will be reviewed for study design, standard 
of adherence, outcomes, strengths, and weaknesses.     
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RESULTS 
Diabetic adherence studies without intervention 
An overview of the studies reviewed with measurements of adherence 
behavior and associated HbA1c are presented in Table 3.  Out of the fourteen 
studies in this category, seven are based on self-reported adherence data 
(including Morisky scales), six on pharmacy refill data, and one on electronic 
monitoring device data.  Although many studies included both T1DM patients and 
T2DM patients, the majority of the patients have T2DM due to the prevalence in 
the population and age restrictions.  Nine studies gathered adherence data for 
general prescription medications of the patients and did not exclude non-diabetic 
medication.  Nine studies provided some kind of HbA1c data, three of which 
defined certain levels of HbA1c as categorical values and reported the percentage 
of population that falls under these categories.  
  22 
Table 3. Diabetic adherence studies: This is an overview of the diabetic adherence studies that contain measurements with 
no intervention. 
Reference T2 / 
T1 
Duration 
of Study 
n Age (years) Medication Adherence 
Method 
Adherence 
Rate 
HbA1c (%) 
(Grant, Devita, 
Singer, & Meigs, 
2003) 
T2 -- 128 66 ± 12 4.1 ± 1.9 types Self-report 
(out of 7days) 
6.7 ± 1.1 days 7.7 ± 1.5 
(Ciechanowski, 
Katon, & Russo, 
2000) 
Both 120 days 367 61.3 ± 11.7* OHA  (Oral 
Hypoglycemic 
Agents) 
Refill data  
(days in OHA 
interruption) 
Depression 
Low 7.1 ± 12  
Med 9.3 ± 15.5  
High 14.9 ± 
20.0 
-- 
(Broadbent, Donkin, 
& Stroh, 2011) 
Both -- T1 49 
T2 108 
43.2 ± 20.6 
T1, 58.0 ± 
11.3 T2 
Mixed Self-report Insulin 
86%  
-- 
(Donnelly, Morris, & 
Evans, 2007) 
T2 6.75 yrs 1099 61.5 ± 11.9 Insulin Database 
(>80% MPR 
cutoff) 
71 ± 18 %  8.5 ± 1.3  
(Lin et al., 2004) Both 2 yrs 4385 63.3 ± 13.4 OHA  Pharmacy 
data 
(days not 
covered) 
80.5 %* 7.8 ± 1.6 
(Pladevall et al., 
2004) 
Both 3 years 677 63.9 ± 10.6 OHA;  
2.1 types 
Refill data 
gaps >20% 
non-adherent. 
Metformin 
57%* 
 
8.0 ± 1.4  
(Bailey et al., 2012) Both -- 59 50.4 ± 10.3 Mixed. >50% 
taking 3 or more.  
Morisky Scale 
(0-6 = non-
adherent 
 7-8 = 
adherent) 
44.1%  -- 
(Al-Qazaz et al., 
2011) 
T2 -- 505 58.2 ± 9.2 Mixed.   
Median 4.0 
Morisky Scale Median 6.5  Good (≤6.5) 
20.8%, Poor 
(≥6.5)79.2% 
* indicates an adherence number calculated by subtracting non-adherence data. 
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Table 3 continued. Diabetic Adherence Studies: This is an overview of the diabetic adherence studies that contain 
measurements with no intervention. 
Reference T2 / 
T1 
Duration 
of Study 
n Age (years) Medic
ation 
Adherence 
Method 
Adherence 
Rate 
HbA1c (%) 
(Stuart et al., 
2011) 
Both 3 years Statin 
1139 
RAAS 
1766 
~85% > 65 y.o. Mixed Logs and 
Pharmacy 
Receipts (Diaries).  
Medication 
Possession Ratios 
(MPR) 
Median MPR 
RAAS = 0.88 
Statins = 0.77.   
% adherence 
RAAS >50% 
Statin <50% 
-- 
(Ngo-Metzger, 
Sorkin, Billimek, 
Greenfield, & 
Kaplan, 2012) 
T2 2 yrs 1135 
 
White 61±10.8, 
68.7±8.9 Viet, 
55.6±10.9 Mex  
Mixed Self-Report White 72.8% 
Vietnamese 
72.4% 
Mexican 46.8% 
Poor Glucose 
Control = A1C >/= 
8%.  White: Poor = 
15.6%, Viet: Poor = 
10%, Mex: Poor = 
45.2%, p<0.001 
(Osborn et al., 
2011) 
Both -- 383 54.4±13.0 Mixed Self-Report, 
SDSCA Scale 
Score (out of 7 
days) 
Average 6.7 ± 
1.0 
Average 7.6 ± 1.7,  
White 7.4±1.5, 
Black 7.9 ± 1.9, 
p=0.005 
(Aikens & Piette, 
2013) 
T2 -- 287 56.4±8.7 Mixed 4 Item Morisky 
Scale 
51% 59% of participants 
had HbA1c>7% 
(Nagrebetsky et 
al., 2012) 
T2 1-2yrs 1yr 
161 
Non 
 50 
1yr  
63.5 ± 10.4 
non  
62.1 ± 11.7 
1yr  
5.0 ± 
2.5 
Non 
4.6 ± 
2.8 
Electronic 
Monitoring system 
(TrackCap) 
Medication 
Adherence Report 
Scale (MARS, 
scale ranged from 
5-25)  
TrackCap 
1yr  75.5 ± 28.3 
non 68.2 ± 28.8 
MARS: (avg) 
1yr 24  
Non 25  
1yr 8.2 ± 1.1 
non 8.6 ± 1.4  
(Virdi, Daskiran, 
Nigam, Kozma, 
& Raja, 2012) 
T2 365 days 5172 51.4 ± 8.4 Non-
insulin  
Refill Data 
MPR (>80%)  
44.4% -- 
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Table 4. Average HbA1c: The mean and standard deviation of HbA1c from 
seven studies 
Reference n Mean HbA1c (%) Standard 
Deviation 
(Grant et al., 2003) 128 7.7 1.5 
(Donnelly et al., 2007) 1099 8.5 1.3 
(Lin et al., 2004) 4385 7.8 1.6 
(Pladevall et al., 2004) 677 8.0 1.4 
(Osborn et al., 2011) 383 7.6 1.7 
(Nagrebetsky et al., 
2012) 
161 8.2 1.1 
50 8.6 1.4 
Weighted Mean and pooled SD: 7.9 1.5 
  
Average percentages of HbA1c were given by six studies.  They ranged 
from 7.6% to 8.6% with a weighted average of 7.9% and a pooled standard 
deviation of 1.5% (Table 4).  The Nagrebetsky data was divided into two groups 
and thus accounted for two separate samples when the weighted average was 
calculated (Nagrebetsky et al., 2012).  Percentages of adherence were 
presented by nine studies (Table 5a) and ranged from 44.1% to 86%.  The 
weighted average for all nine studies came out to be 61.4 ± 15.8% (Table 5b).  A 
comparison of the weighted average of adherence rate for six self-report studies 
and four database studies was carried out in Table 5b.  A p-value was produced 
as a result of a t-test for the null hypothesis that the self-report average was 
different from the database average (H0: μself-report ≠ μdatabase).  Since p= 0.47, the 
analysis was not statistically significant and the null is rejected, indicating that the 
average adherence from self-reported data was not significantly different from 
the database average.    
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Table 5a. Average adherence rate (%): Percent of patient adherent in ten 
studies 
Reference Method n Adherence rate (%) 
(Broadbent et al., 2011) Self-report 157 86 
(Ngo-Metzger et al., 2012) 
Self-report 
(Non-hispanic white) 
249  72.8 
(Ngo-Metzger et al., 2012) 
Self-report 
(Vietnamese) 
194 72.4 
(Ngo-Metzger et al., 2012) 
Self-report 
(Mexican) 
 
533 46.8 
(Bailey et al., 2012) Self-report Morisky scale 59 44.1 
(Aikens & Piette, 2013) Self-report Morisky Scale 287 51 
(Donnelly et al., 2007) Refill data (>80% MPR) 1099 71 
(Lin et al., 2004) Refill data (>80% MPR) 4385 80.5 
(Pladevall et al., 2004) Refill data (<20% CMG*) 677 57 
(Virdi et al., 2012) Refill data (>80% MPR) 5172 44.4 
*CMG = continuous measure of medication gaps 
 
 
Table 5b. Weighted average of adherence rate (%): Calculated average 
adherence rate of studies in Table 5a. 
Total Self-report  Refill data p-value 
61.4 ± 15.8% 59.4 ± 17.4% 61.7 ± 15.9% p= 0.47 
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Several studies have noted the significant association between increased 
medication adherence and improved clinical outcomes, especially in long term 
metabolic control (Aikens & Piette, 2013; Al-Qazaz et al., 2011; Donnelly et al., 
2007; Pladevall et al., 2004).  One study noted that there is no significant 
association between glycemic control and age, gender, or social deprivation 
(Donnelly et al., 2007).   Other studies attempted to control for various factors 
that might have affected the outcome of the adherence data (Table 6). 
 Grant et al hypothesized that the number of prescription medications a 
patient has to take can contribute to poor adherence (Grant et al., 2003).  They 
utilized correlation studies and found the Spearman’s correlation coefficient for 
number of medications taken and adherence rate to be 0.07 (p= 0.4).  The 
finding was not statistically significant.   
Two studies focused on the effect of depression on compliance to diabetic 
medication regimen (Ciechanowski et al., 2000; Lin et al., 2004).  Both studies 
only focused on OHAs and found that there is significant evidence (p<0.05, 
p<0.005 respectively) that patients with major depressive symptoms tend to have 
poorer adherence to diabetic medication.   
The study by Bailey et al concluded that the significant (p<0.05) factors 
that are associated with medication non-adherence are “cost, no refills, poor 
health status, fewer disease states, and any reason at all to not take medication 
(Bailey et al., 2012).”  When diabetic knowledge was assessed, Al-Qazaz et al 
found that patients with better glycemic control (HbA1c ≤ 6.5) had higher 
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adherence rates (p<0.001) and also more knowledge about diabetes (p<0.001) 
(Al-Qazaz et al., 2011).   
When adherence rate was assessed by race, it was clear that Mexican 
Americans and African Americans had the lowest adherence rates compared to 
Whites in the US (Ngo-Metzger et al., 2012; Osborn et al., 2011).  Ngo-Metzger 
et al found that more Mexican Americans reported to have financial barriers and 
lower overall income compared to Whites and Vietnamese Americans (Ngo-
Metzger et al., 2012).  Osborn et al. found that while African Americans had 
significantly lower adherence rate (p<0.05), they also had lower health literacy 
(Osborn et al., 2011).  When numeracy was assessed, no significant results were 
found.   
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Table 6. Factors associated with non-adherence: This shows some studies that tried to control for factors that associate with non-
adherence 
Reference Factor studied Results Significance  Conclusion 
(Grant et al., 
2003) 
Number of 
medication 
taken by patient 
Spearman’s correlation coefficient for 
number of medication vs. adherence = 
0.07 
p=0.4 
Not significant  
Virtually no correlation 
between total number of 
medication and average 
medication adherence 
(Ciechanowski 
et al., 2000) 
Depression  Depression & Adherence (% days in 
OHA interruptions) 
Low dep. 7.1 ± 12  
Med dep. 9.3 ± 15.5  
High dep.14.9 ± 20.0 
p<0.05 
Significant 
Depression severity is 
significantly associated with 
poor adherence 
(Lin et al., 
2004) 
Depression Major dep. 24.5% non-adherence 
No Major dep 18.8% non-adherence 
p<0.005 
Significant 
Depression is significantly 
associated with non-adherence 
(Bailey et al., 
2012) 
Access, 
barriers, 
medication use, 
and 
demographics 
Adherence data for specific categories 
were not given 
P<0.05 for Cost, no 
refills, poor health 
status, fewer disease 
states, and any 
reason 
Cost, no refills, poor health 
status, fewer disease states, 
and having any reason at all 
are significantly associated 
with non-adherence. 
(Al-Qazaz et 
al., 2011) 
Diabetes 
knowledge 
A1c ≤ 6.5 10 MDKT* 8 MMAS
 †
 MDKT* 
p<0.001 
MMAS
 †
 
p<0.001 
More knowledge about 
diabetes is correlated with 
better adherence rate and 
better glycemic control. 
A1c > 6.5 7 MDKT* 5.8 MMAS
 †
 
(Ngo-Metzger 
et al., 2012) 
Financial 
barriers and 
race 
Adherence White 
72.8% 
Viet 
72.4%  
Mexican 
46.8%  
p<0.001 for all 
measures between 
white and Mexican or 
Viet and Mexican 
Mexicans had lower adherence 
rate and poor glycemic control.  
Mexicans also reported more 
financial barrier. 
A1c≥8% 15.6% 10.0% 45.2% 
(Osborn et al., 
2011) 
Race, Diabetes 
literacy, and 
numeracy 
White Adherence 
6.8 ± 0.8 SDSCA
‡
 
Black Adherence 
7.9 ± 1.9 SDSCA
‡
 
p<0.05  African Americans had lower 
adherence, but this could be 
due to health literacy.  Health literacy vs. Adherence r=-0.1 p<0.02 
* MDKT = Michigan Diabetes Knowledge Test (0-14).  Higher score indicates more knowledge. 
†
 MMAS = Morisky Medication Adherence Scale (0-8).  Higher score indicates better adherence. 
‡ 
SDSCA = Summary of Diabetes Self-Care Activities.  This is the number of days being adherent to medication in the past 7 days. 
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Intervention 
Twelve studies were reviewed regarding interventions to improve 
medication adherence in diabetes (Table 7).  Although many studies measured 
MPR as a means of adherence, due to the differences in measurement methods, 
the results are difficult to compare across studies.   
One study (Maciejewski, Farley, Parker, & Wansink, 2010) utilized a cost-
based intervention in which the researchers studied enrollees in a value-based 
insurance design program, from which the sample of the intervention group was 
drafted.  These patients received significant copayment reductions based on the 
type of medication prescribed and whether or not the medication was from a 
name brand.  The control group consisted of patients who were not enrolled in 
the value program.  Using a pre-post quasi-experimental study design, 
Maciejewski et al. assessed changing MPR percentages for a series of 
medications.  For the purposes of this paper, the data for metformin was 
specifically examined.  The study showed that there was a significant decrease in 
adherence for patients who were not enrolled in the copayment reduction 
program (p<0.001). No clinical outcomes were assessed.  
Four of the twelve studies can be classified as convenience-based 
interventions.  Of these four, two studied a change in method of insulin 
administration (vial/syringe to pen) in order to increase adherence.  Xie et al. 
conducted a pre-post study with two groups of patients (Xie et al., 2013).  The 
intervention group switched to pens, while the control group continued to use 
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vials and syringes.  Lee et al., on the other hand, studied the adherence rate of 
one group of patients who had switched to pens (W. C. Lee, Balu, Cobden, 
Joshi, & Pashos, 2006).  Xie et al. demonstrated that there was a significant 
difference between the intervention group and the control group in adjusted 
MPRs after the switch (p<0.05).  They also showed that persistence was 
significantly longer for patients who had switched to the insulin pen (p<0.0001).  
The other study showed that the percentage of patients who met the adherence 
cutoff (MPR > 80%) increased significantly after switching to insulin pens 
(p<0.01).  While Lee et al. did not conduct studies on clinical outcome, Xie et al. 
observed the change in patients’ HbA1c and found no significant difference 
between the intervention group and the control group (p=0.09).   
One of the other convenience-based intervention studies examined the 
difference in adherence between once-daily and twice-daily dosages for Glipizide 
(Dezii et al., 2002).  The study demonstrated that adherence was significantly 
greater in once-daily dosage patients (p<0.05). The last convenience-based 
intervention study looked at differences in prescription medication acquisition 
(Zhang et al., 2011).  The intervention group used mail-order pharmacy services, 
where prescription medications can be delivered to the patients’ residences 
directly, while the control group utilized retail pharmacies.  PDC (proportion of 
days covered) was assessed, and it was found that the intervention group had a 
significantly higher adherence rate (p<0.001).  No clinical data was presented by 
either of these two studies.   
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Five of the twelve articles fall under the category of communication-based 
interventions.  Patel et al. and Vervloet et al. conducted their studies with 
electronic monitoring devices that could send reminders to patients during the 
time in which they needed to take their daily medications (Patel et al., 2013; 
Vervloet et al., 2012).  Patel et al. performed a pre-post analysis and compared 
the PDC ratio of patients before activation of the mobile application and during 
the 30days in which the patient utilized the application.  The difference between 
the pre-activation adherence and the post-activation adherence was not 
significant; however, it approached significance (p=0.057).  They also had a 
seven months follow-up where the adherence rate fell below the pre-activation 
period.  Vervloet et al. differed from Patel et al.’s study in that the former used a 
control group that did not receive a reminder system.  They measured “days 
without dosing” and found that there was no significant difference between the 
intervention and control groups (p=0.283).  However, due to the functionality of 
the electronic monitoring system, they were able to obtain time stamped 
information regarding how readily the patient took the dosage within the allotted 
time slot (ranged from 15 – 45 minutes).  The difference between the percentage 
of doses taken within this time slot between the intervention group and control 
group was significant (I: 56.7± 23.8% vs. C: 43.2± 26.2% p=0.003).  No clinical 
data was obtained through these two studies. 
 The remaining three of the five communication-based interventions 
articles focused on education and emotional support from healthcare providers.  
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Walker et al. examined the effect of telephone calls to patients from health 
educators on medication adherence (Walker et al., 2011).  The telephone calls 
were made to the intervention group and provided information regarding 
medication adherence and life style changes.  The control group did not receive 
telephone calls; however, both groups received printed educational materials.  
MPR was calculated from refill data. Although specific numerical data was not 
found on the article, the authors reported that there was no significant difference 
between those who received phone calls and those who did not.   
Shah et al. studied the effects of pharmacist discharge counseling on 
adherence (Shah et al., 2013).  The intervention group received counseling 
regarding their disease status and medication regimen from pharmacists before 
being discharged from the hospital, while the control group was not counseled.  
The PDC calculated from refill data for the intervention group was significantly 
higher than that of the control group (p<0.005).  Clinical outcomes were taken 
into consideration in the form of long-term glycemic control.  The average HbA1c 
for the intervention group turned out to be significantly lower that of the control 
group (p<0.005).   
Stanger et al. was the only T1DM specific study in the intervention study 
pool reviewed by this paper (Stanger et al., 2013).  This 14-week pre-post study 
involved providing adolescents with T1DM motivational counseling in conjunction 
with contingency management in order to improve blood glucose monitoring 
frequency (BGM).   Free glucometers and test strips were also provided to the 
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subjects.  This study assessed adherence through self-reported daily frequency 
of BGM as part of the treatment regimen.  A baseline BGM was established prior 
to the introduction of the intervention.  It was found that the daily BGM frequency 
increased significantly as a result of the intervention (p<0.001).  As for the clinical 
outcomes, HbA1c decreased significantly over the course of the study (p<0.0001).  
Furthermore, a three-month follow-up showed no significant difference in HbA1c 
compared to the measurements obtained right after the intervention (p=0.42).     
Of the featured articles, two fit within the reward-based intervention 
category.  Both studies utilized financial incentives as the reward.  Austin & Wolfe 
studied patient populations that had not had HbA1c or LDL screenings in the past 
year (Austin & Wolfe, 2011).  Adherence to regular clinical screenings was 
assessed through lab results on file.  The intervention group received a $6 gas 
station gift card every time a lab result was sent to the health-care provider, while 
the control group did not receive anything.  Although numerical data was not 
presented in the article, the authors reported that the intervention group had 
significantly higher average number of screenings.  The clinical outcome had a 
positive trend in HbA1c reduction associated with number of screenings but the 
result bore no significance.   
Long et al. conducted their research using two different interventions 
(Long, Jahnle, Richardson, Loewenstein, & Volpp, 2012).  Intervention group 1 
was received telephone peer mentoring and the mentors were provided $20 
incentive to talk with the subjects every month for six months.  Intervention group 
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2 was a reward-based group where they received $100 for achieving 1% 
reduction in HbA1c at the end of the six months and $200 for 2-6% reduction.  A 
control group was also established receiving regular care with the lack of peer 
mentoring and financial incentives.  Adherence data was obtained through 
patient self-report.  Intervention group 1 achieved a 79% adherence rate, and 
intervention group 2 had an 80% adherence rate compared to the 67% achieved 
by the control group.  Although a p-value was not presented for the difference in 
adherence, it is clear that the numbers are quite different between the 
intervention groups and the control group.  HbA1c was measured before and after 
the study in an effort to assess clinical outcomes.  Change in HbA1c was 
presented in the article.  Although there is no significant change in HbA1c for any 
of the groups before and after the study (p>0.05), intervention group 1 had 
achieved significantly higher reduction in HbA1c than the control group (p<0.01).   
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Table 7. Overview of intervention studies: Findings from the intervention studies including adherence and 
clinical outcomes 
Reference N Intervention Control 
Adherence measure 
and results 
Sig.  
Clinical 
outcomes 
Sig. 
(Maciejewski 
et al., 2010) 
nI = 2201 
nc= 2201 
Enrollment in program 
for reducing 
copayment based on 
need, drug type (band 
vs. non-brand) 
Not enrolled 
in the 
program.  
Normal 
copayment 
MPR %decrease 
(Metformin) 
 
I: ∆ ~0% 
C: ∆ ~-3.8% 
p<0.001 
for the 
difference 
significant 
-- -- 
(Xie et al., 
2013) 
nI = 603 
nc= 603 
Switching from 
vials/syringe to pens 
for insulin 
administration 
Continued 
use of 
vials/syringe 
MPR (adjusted for the 
difference b/w pen and 
vial) 
 
Intervention: 
Pre 0.86 ± 0.18 
Post 0.79 
Persistence: 65.3% 
 
Control:   
Pre 0.86 ± 0.17 
Post 0.76 
Persistence: 49.8% 
MPR post 
p=0.017 
Significant 
 
Persistence 
p<0.0001 
significant 
∆ HbA1c% 
 
I: -0.04% 
 
C: -0.24% 
p=0.09 
Not 
significant 
(W. C. Lee et 
al., 2006) 
n=1156 
Pre-post 
analysis 
After switching from 
vial/syringe to pens for 
insulin administration 
Before 
switching to 
pen  
MPR (>80% as 
adherent) 
 
I: 54.6% 
C: 36.1% 
p<0.01 
significant 
--  -- 
(Dezii et al., 
2002) 
nOD =746 
nBID = 246 
Once-daily dosage for 
Glipizide (OD) 
Twice-daily 
dosage for 
Glipizide 
(BID) 
Adherence Index 
(similar to MPR) 
 
OD: 60.5% 
BID: 52% 
p=0.027 
significant  
-- -- 
I = intervention group      C = control group    
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Table 7 continued.  Overview of intervention studies 
Reference N Intervention Control 
Adherence measure 
and results 
Sig.  
Clinical 
outcomes 
Sig. 
(Zhang et al., 
2011) 
nI=1361 
nC=1361 
Mail-order pharmacy Retail 
pharmacy 
PDC* (same as MPR) 
I: 49.7% 
C: 42.8% 
p<0.001 
-- -- 
(Patel et al., 
2013) 
n=50 
Pre-post 
study 
I1: During the 
activation of Pill Phone 
(Mobile application for 
medication reminder) 
 
I2: Post activation of 
Pill Phone 
Pre-
activation of  
Pill Phone 
PDC (same as MPR) 
 
I1: 0.58 
I2: 0.46 
C: 0.54 
C vs. I1 
p=0.057 
approaches 
significance -- -- 
(Vervloet et 
al., 2012) 
nI=56 
nC=48  
Real time medication 
monitoring system that 
has customized SMS 
medication reminder 
system built in.   
Regular 
care without 
the real time 
medication 
monitoring 
system 
Days without dosing 
I: 11.9 ± 18.8 
C: 13.8 ± 14.5 
 
Dose taken within time 
period (range from 
15min to 45min) 
I: 56.7% ± 23.8% 
C: 43.2% ± 26.2% 
p=0.283 
not significant 
 
 
p=0.003 
significant 
-- -- 
(Walker et al., 
2011) 
nI=262 
nc=264 
Telephone calls from 
health educators 
about medication 
adherence and life 
style changes. 
Regular 
care with 
printed 
educational 
materials 
(intervention 
group also 
received 
printed 
materials) 
MPR 
 
Numerical data not 
presented 
p=0.23 for 
insulin users 
 
p=0.39 for 
non-insulin 
users 
 
Not 
significant 
-- -- 
*PDC = Proportion of days covered 
  37 
Table 7 continued.  Overview of intervention studies 
Reference N Intervention Control 
Adherence measure 
and results 
Sig. 
Clinical 
outcomes 
Sig. 
(Shah et al., 
2013) 
nI = 64 
nc = 64 
Pharmacist discharge 
counseling  
Regular 
care 
PDC (same as MPR) 
I: 55.2% ± 42.0% 
C: 34.8% ± 37.9% 
p=0.004 
significant 
HbA1c (%) 
I: 7.8±1.6 
C: 9.5±2.9 
p=0.003 
(Stanger et 
al., 2013) 
n=17 
Pre-post 
study with 
a follow-
up 
 
Adolescen
ts with 
T1DM 
Motivational interview 
and contingency 
management that 
targeted increased 
Blood Glucose 
Monitoring (BGM).  
Free glucometer and 
test strips were 
provided 
Regular 
care before 
intervention 
Self and parent-report 
of BGM 
 
Average frequency of 
BGM per day 
 
Pre: 4.1±1.9 
Post: 6.3±2.0 
 
p<0.001 HbA1c (%) 
 
Pre:  
11.6 ± 2.5 
Post:  
9.1 ± 0.9 
3m Follow-
up: 
9.8 ± 1.4 
 
Pre vs. 
Post 
p<0.0001 
Significant 
 
Post vs. 
Follow-up 
p=0.42 
Not 
significant 
(Austin & 
Wolfe, 2011) 
nI = 464 
nc = 2101 
 
Patients 
lacking 
HbA1c 
screening 
$6 gas gift card 
incentive for each lab 
result received by 
doctors.   
Regular 
care 
Avg number of HbA1c 
screenings 
 
I: 3.34  
C: 2.69 
Significant 
difference, p 
value not 
given 
Positive 
trend  
No 
significance 
(Long et al., 
2012) 
n1 = 38 
n2 = 40 
nc = 39 
 
African 
American 
veterans 
with poor 
diabetes 
control 
I1: Telephone peer 
mentoring.   
 
I2: At the end of six 
months, $100 for 1% 
decrease in HbA1c 
and $200 for 2-6% 
decrease in HbA1c 
Regular 
care 
% of patient with self-
reported good 
adherence  
 
I1: 79% 
I2: 80% 
C: 67% 
Not given ∆HbA1c(%) 
from 
baseline 
I1: -1.08 
I2: -0.46 
C: -0.01 
 
∆from C 
I1: -1.07 
I2: -0.45 
p>0.05 for 
all ∆HbA1c 
from 
baseline.  
 
p<0.01 for 
I1 vs. C 
 
p=0.25 for 
I2 vs. C 
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Adherence studies on non-diabetic diseases 
Many articles were found of adherence studies on non-diabetic disease.  
Some of the studies on diseases most relevant to diabetes such as hypertension 
and cardiovascular diseases were briefly reviewed.   
 Irvine et al. examined the difference in adherence and mortality between a 
placebo group and a group using amiodarone therapy.  Subjects are mainly 
acute myocardial infarction survivors.  Adherence was measured through pill 
count and patients who have an average-count less than the 20th percentile were 
considered to be poorly-adherent.  The study found that those who are poorly-
adherent in both the amiodarone group and the placebo group had a significantly 
increased risk for sudden cardiac death (p<0.01, p<0.05 respectively), total 
cardiac mortality (p<0.01, p<0.02), and all-cause mortality (p<0.004, p<0.001).  
The study identified that age above 70 years old was a predictor of poor 
adherence to placebo (p<0.03).  They have also found that the lack of social 
activities was also correlated with reduced adherence (p<0.05) (Irvine et al., 
1999).   
 In a study for hypertension, Friedman et al. conducted an experiment to 
assess the effect of a telecommunications system that monitored and counseled 
patients on adherence to antihypertensive medications as well as blood pressure 
control (Friedman et al., 1996).  The control group received usual care with no 
telephone systems.  Adherence data was evaluated through pill count of 
antihypertensive medications.  Mean adherence improved significantly for the 
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intervention groups compared to the controls (p<0.05).  Blood pressure was 
assessed as a mean for clinical outcomes.  The mean diastolic blood pressure 
decreased significantly for intervention group compared to the controls as well 
(p<0.05).   
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DISCUSSION 
Baseline adherence rate and HbA1c 
 The first part of this review was focused on nonintervention diabetic 
adherence studies that either helped to establish a baseline adherence rate or 
provided insight to certain factors that interfere with adherence.  One of the 
biggest problems with the studies provided is the lack of standardization in 
adherence measurement and analytic strategies.  The self-report method 
presented the greatest variety in evaluation of adherence.  In the seven self-
reported studies, three utilized the Morisky scale of adherence.  Although the use 
of Morisky scales has provided these three studies with some standardization, 
the presentation of results was completely different amongst the studies.  Bailey 
et al. classified a score of 0-6 as non-adherent and 7-8 as adherent, whereas Al-
Qazaz et al. only provided a median score with no classification.   
 Studies that used refill data as a source of adherence measurement 
showed more uniformity in analysis strategies.  With the exception of one, all of 
these studies calculated some form of the medication possession ratio and set 
the cut-off for whether a subject is considered adherent or not at >80%.   
Out of the fourteen articles reviewed in this category, ten articles 
evaluated adherence as categorical variables in the form of self-reported status, 
Morisky scale scores, or dichotomous variable with a percentage cutoff.  These 
studies were able to provide percentages of subjects that were adherent during 
the study and thus the data was compared.  The total average of the proportion 
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of subjects who were considered to be adherent across the ten studies is 61.4 ± 
15.8%.  This number is slightly lower than the previously reported average 
adherence rate of 70% (DiMatteo, 2004); however, this could be due to the fact 
that only a limited number of articles were reviewed in this paper.   
Since patient self-report has a tendency to overestimate adherence rate 
(McDonald, Garg, & Haynes, 2002; Vermeire et al., 2001), the average 
adherence rate from the self-reported studies were compared to the average 
calculated using refill data.  The two averages were not significantly different, 
indicating that self-report was just as effective at assessing adherence rate as 
the refill data.  However, due to the limited number of studies reviewed, this 
result lacks power in determining the true difference.   
Nine studies out of the twelve provided data on HbA1c.  Variation in data 
analysis and presentation has once again limited the number of studies that can 
be compared.  The weighted mean HbA1c of subjects in six studies is 7.9 ± 1.5% 
and the data ranged from 7.6% to 8.6%.  This number is feasible considering that 
the subjects studied are diagnosed with DM (>6.5% HbA1c).   
 
Poor adherence and barriers to adherence 
 Four studies have confirmed that increased medication adherence rate is 
associated with improved long term metabolic control (Aikens & Piette, 2013; Al-
Qazaz et al., 2011; Donnelly et al., 2007; Pladevall et al., 2004); however, it is 
unclear whether medication adherence is the main factor contributing to the 
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change in glycemic control.   Donnelly et al. has found no significant association 
between glycemic control with age, gender, or social deprivation.  Since there are 
previous reports that old age (>70yrs) is a predictor of poor-adherence (Irvine et 
al., 1999), the discrepancy might be due to the study design and patient 
population.     
 Some predictors of poor-adherence are identified through the studies 
presented.  Identification of patients with poor-adherence would be helpful to 
healthcare providers in order to provide interventions.   Depression and race 
(African American and Mexican American) are shown to be significantly 
associated with poor-adherence (Ciechanowski et al., 2000; Lin et al., 2004; 
Ngo-Metzger et al., 2012; Osborn et al., 2011); however, these factors are 
merely associated with decreased adherence with no demonstrated causation 
relationship.   For example, Ngo-Metzger et al. found that Mexican Americans 
had significantly lower adherence rates that correlated with their overall lower 
household income and higher reported financial barriers.  In the same study, they 
found that financial barriers are associated with lower adherence and higher 
HbA1c (p<0.001).   Other studies also found that higher healthcare cost is a barrier 
to adherence along with other factors such as lack of refills, poor health status, 
and poor diet (Bailey et al., 2012; Ciechanowski et al., 2000).   
In the case of Osborn et al.’s study, where African Americans had lower 
adherence rate compared to whites, they hypothesized that diabetes literacy and 
numeracy might be the barrier causing the difference in adherence.  The 
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research found significant evidence that low health literacy in African Americans 
was one of the reasons explaining the lowered adherence rate, but no clinical 
evidence was examined.   
 Factors that were studied but presented no significant correlation to 
adherence are polypharmacy number greater than 1 (number of prescribed 
medications is greater than 1), diabetes numeracy, and the utilization of 
electronic medication monitoring devices (Grant et al., 2003; Nagrebetsky et al., 
2012; Osborn et al., 2011).   Although all three studies had sample sizes (n) 
greater than 60, the study could still present biases and confounding variables 
that make the factors seem irrelevant even if it is. 
 
Intervention 
 Twelve intervention studies were reviewed that included at least one of 
each of the intervention types discussed in the introduction.   Five of the studies 
presented both medication adherence and clinical outcomes in the form of HbA1c.    
Two studies showed no significant change to the adherence and two other 
studies showed no significant change to the long-term glycemic control after 
subjects had received the intervention.  Three studies used pre-post study 
designs and assessed the difference before the intervention and after the 
intervention with the same group of subjects.  These studies could be 
underestimating the effects of the intervention due to the lack of control 
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comparison and the additional effects that time could have on the adherence 
rate.   
 There are several problems with intervention studies as a whole.  First of 
all, the subject selection process is flawed.  Although many studies randomly 
select a list of patients who qualify for their study, only the patients who are 
voluntarily choosing to participate are recruited.  This lack of true randomization 
means the intervention studies might fail to evaluate the patient population that 
are unwilling to seek care.  It would be better to design a study where patients 
who are overdue for medical attention be contacted and given information 
regarding the study and intervention so that more patients of that type could be 
consented into participating in the study. 
 Secondly, adherence data are often gathered during the intervention 
process or a short amount of time following the intervention.  It is rare to see any 
studies address the long-term benefits of the intervention, or even present data 
on what happens when the intervention is terminated.  Most follow-up periods are 
around three months to six months and one can already observe a decrease in 
the previously increasing adherence rate (Patel et al., 2013; Stanger et al., 
2013).  Since diabetes is a chronic disease, an intervention should focus on 
having a long lasting effect.   This means that both interventions and follow-ups 
have to last sufficiently long in order to gather meaningful results regarding 
adherence. 
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 In addition, a number of studies had sample sizes that are too small.  A 
study with small sample size would lack the power to distinguish differences in 
the data.  One can calculate the required sample size through tables or statistical 
methods.  Without an adequately large sample size, it would be difficult to 
interpret the data and extrapolate the findings. 
 It was surprising to see that both studies that focused on electronic 
reminder devices failed to make significant differences in adherence rate (Patel 
et al., 2013; Vervloet et al., 2012); however, upon closer examination, it seems 
that the devices were able to produce significant increase in doses taken by the 
patients within the recommended time period.  This means that, although the 
device did not help increase long term adherence or persistence, it was able to 
help patients take their medication at the right time during the day.  This could be 
very useful for complex medication regimens that require multiple dosages within 
a day.   
   The study done by Long et al. showed rather interesting results.  One of 
the intervention groups received peer counseling and the mentors received 
monthly financial incentives to carry out the peer counseling, while the other 
intervention group received one incentive at the very end of the study for 
reducing HbA1c.  Both groups had significantly higher adherence rate compared 
to the control group at the end of the study.  However, the clinical outcomes did 
not quite match the adherence data.  The group that received peer counseling 
had significantly lower HbA1c than the control group, but the average HbA1c of the 
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group that received a final incentive was not significantly different from that of the 
control.  Although this outcome can be interpreted in many ways, it could suggest 
that while the second intervention helped increasing adherence rate, some other 
factor might have more influence on improving glycemic control, such as the 
emotional aspect of interacting with another human being through counseling.  
However, the lack of monthly financial incentives given to the patients provides 
no assessment of whether financial incentives could work the same way as the 
monthly peer mentoring if provided in a shorter period in between.   
 This idea that adherence rate is not the only factor affecting clinical 
outcomes can be further demonstrated by the study conducted by Irvine et al., 
where poor adherence in both the placebo group and the medication group 
increased mortality rate significantly.  This result suggests that poor adherence to 
medication is only part of the problem; there is a greater underlying behavioral 
factor that is hindering the effectiveness of treatments.    
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CONCLUSION 
Poor adherence is common in patients with DM and other chronic 
diseases that require extensive self-management.  This behavior has been linked 
to increased complications, mortality rate, and health care costs.  Although old 
age, race, and symptoms of depression are predictors of poor adherence, high 
health care costs, poor health status, and poor diet act as barriers preventing 
patients from being compliant with their medication regimens.   
Much effort has been put into finding ways to improve adherence, and 
these interventions have shown varied results in altering medication possession 
rates.  One of the biggest problems with studies in this field is the lack of 
standardized methods in measuring true adherence.  The use of pharmacy and 
patient self-report data might be more cost-effective, but they provide no 
assessment on whether a patient has actually taken the medication.  It would be 
critical for future studies to incorporate more direct methods such as blood and 
urine tests to monitor the actual adherence rate of subjects. 
The lack of a meaningful measurement of true adherence also renders the 
studies on clinical outcomes less conclusive.  From the reviewed intervention 
literatures, only three have shown significant improvement in HbA1c.  All three 
studies used communication based interventions that focused on changing the 
subjects’ behaviors as a whole.  Although both adherence rate and glycemic 
control have improved in these cases, there is no indication that the improved 
adherence rate was the cause of these positive clinical outcomes.  Furthermore, 
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while some interventions can provide a short-term improvement, there is no 
evidence that these interventions can maintain the positive effects consistently 
for a long period of time.  Since diabetes mellitus is a chronic disease, it would be 
important to design interventions that could maintain long-term effects. 
The most important question to consider is whether changing medication 
adherence alone is enough to solve the problems posed by poor patient self-
care.  Perhaps the focus should be shifted towards identifying factors that could 
provide enough motivation to the patients to change their behavior and ultimately 
improve their health.     
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